文献速递神经肿瘤

脑膜瘤伽玛刀放射外科治疗的十年随访及文献回顾

Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature.
PubMed 文献 · Acta Neurochir (Wien) · 2020-06-26

该研究回顾性分析了1991年至2001年间在斯德哥尔摩卡罗林斯卡医院接受伽玛刀放射外科治疗的86例连续瑞典脑膜瘤患者,共治疗130个肿瘤(115次治疗)。中位影像随访10年,中位临床随访9.4年。结果显示中位随访10年后局部肿瘤控制率达87.8%(108/123),72%患者无需进一步治疗,86%患者神经功能稳定或改善;处方剂量>13.4 Gy的脑膜瘤局部复发率显著更低(7.1% vs. 24%,p=0.02)。

要点

  • 伽玛刀治疗脑膜瘤十年局部控制率达87.8%。
  • 处方剂量>13.4 Gy与更低的局部复发率相关。
  • 多数患者(86%)神经功能稳定或改善,72%无需进一步治疗。

核心结论

  • 伽玛刀放射外科治疗脑膜瘤在十年随访中显示持续高局部肿瘤控制率,并提示长期肿瘤控制所需的最低剂量。

研究设计与样本

  • 回顾性分析1991年3月至2001年5月间在斯德哥尔摩卡罗林斯卡医院接受伽玛刀放射外科治疗的86例连续瑞典脑膜瘤患者,共治疗130个肿瘤(115次治疗)。

主要发现

  • 中位影像随访10年(范围1.8-16.5年),中位临床随访9.4年(范围2.1-17.4年)。
  • 中位随访10年后,局部肿瘤控制率为87.8%(108/123个肿瘤)。
  • 初始治疗至局部(野内)复发(n=15)的中位潜伏期为5.8年(范围1.9-11.5年)。
  • 邻近但初始照射野外的复发见于15.1%的患者(13/86),中位时间7.5年(范围1.3-15.7年)。
  • 新发脑膜瘤见于10.5%的患者,中位时间5.4年(范围0.9-10.8年)。

临床怎么用

  • 对于脑膜瘤患者,伽玛刀放射外科治疗可提供持久的局部肿瘤控制,且多数患者无需进一步干预。
  • 处方剂量>13.4 Gy可能与更低的局部复发率相关,但需个体化评估。

局限性

  • 本研究为回顾性分析,样本量有限(86例患者),随访时间范围较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: With regard to the generally slow growth of meningioma, it is essential to analyse clinical treatment results in a long-term perspective. The purpose of the present analysis is to provide clinical data after Gamma Knife radiosurgery of meningioma in a 10-year perspective together with a review of the current literature. METHODS: The current study is a retrospective analysis of 86 consecutive Swedish patients with meningiomas treated using Gamma Knife radiosurgery at the Karolinska Hospital Stockholm between March 1991 and May 2001. A total of 130 tumours were treated in 115 treatment sessions. The median radiological follow-up was 10 years (1.8-16.5 years), and the median clinical follow-up was 9.4 years (2.1-17.4 years). RESULTS: After a median follow-up period of 10 years, local tumour control was achieved in 87.8% of meningiomas (108/123 tumours). The median latency between initial treatment and local (in-field) recurrence (n = 15) was 5.8 years (1.9-11.5). Recurrences adjacent but outside the initial radiation field occurred in 15.1% of patients (13/86) at a median of 7.5 years (1.3-15.7). New meningiomas were seen in 10.5% after a median of 5.4 years (0.9-10.8). In 72% of patients, no further treatment was required, 17.4% (15/86) underwent a second Gamma Knife treatment, 4.7% (4/86) required later open surgery and 5.8% (5/86) required both secondary treatments. Eighty-six percent of patients were neurologically unchanged or improved. A significantly lower rate of local (in-field) recurrences was seen in meningiomas treated with a prescription dose of > 13.4 Gy (7.1% vs. 24%, p = 0.02). CONCLUSIONS: The current retrospective analysis provides a 10-year follow-up and comprises one of the longest available follow-up studies of radiosurgically treated meningiomas. The current series documents a persistent high local tumour control after Gamma Knife treatment, while providing an estimation of a necessary minimum dose for long-term tumour control in meningiomas. The study confirms the validity of previous short-term data in a long-term perspective.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Lippitz BE, Bartek J, Mathiesen T, et al. Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature. Acta Neurochir (Wien). 2020. PMID: 32591948. doi:10.1007/s00701-020-04350-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。